NCT00310427View on ClinicalTrials.gov

Effect of LY686017 on Alcohol Craving

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Alcohol DependenceAlcoholism
Interventions
DRUG

LY686017

50 mg administered orally on a daily basis

DRUG

Placebo

Administered on a daily basis

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

NCT00310427 - Effect of LY686017 on Alcohol Craving | Biotech Hunter | Biotech Hunter